Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 11/20 | 0.34 |
| ▸ | HTR2C | P28335 | 11/20 | 0.34 |
| ▸ | HTR2B | P41595 | 11/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4322406 | 0.98 | PNMT (0.41) | PNMTMAPTADRA2AADRA2BADRA2C | |
| Trifluoroacetic Acid SCHEMBL30321353 | 0.84 | MAPT (0.34) | PNMTMAPTHTR2AHTR2CHTR2B | |
| SCHEMBL7935912 | 0.84 | PNMT (0.42) | PNMTMAPTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL30321337 | 0.84 | HTR2C (0.41) | PNMTMAPTHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL4319515 | 0.84 | HTR2C (0.41) | PNMTMAPTHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL21753155 | 0.82 | PNMT (0.41) | PNMTMAPTADRA2AADRA2BADRA2C | |
| SCHEMBL416988 | 0.82 | PNMT (0.41) | PNMTMAPTADRA2AADRA2BADRA2C | |
| SCHEMBL16916827 | 0.81 | PNMT (0.39) | PNMTMAPTADRA2AADRA2BADRA2C | |
| SCHEMBL12706725 | 0.81 | HTR2A (0.49) | PNMTMAPTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL4328115 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745139-A1 | COMPOUND FOR TREATING AND PREVENTING RESPIRATORY SYNCYTIAL VIRUS INFECTION DISEASES | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-12522570-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| WO-2025011580-A1 | COMPOUND FOR TREATING AND PREVENTING RESPIRATORY SYNCYTIAL VIRUS INFECTION DISEASES | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-16 | — | — | WO | disclosed |
| WO-2024233605-A1 | COMPOUNDS AND THEIR USE AGAINST CANCER | TANGO THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240254091-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| CN-113135924-B | Pyrimidine derivatives and their use in medicine | 广东东阳光药业股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-11827609-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827609-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827609-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230096028-A1 | BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2023-03-30 | — | — | US | disclosed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2090570-A1 | IMIDAZOLE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-08-19 | — | — | EP | disclosed |
| WO-2007070872-A1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254091-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | PNMT 3496/4885MAPT 3599/4885ADRA2A 705/4885 |
| US-20230096028-A1 | BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF | SOST, SOS1, IQGAP1 | PNMT 4662/4885MAPT 3878/4885ADRA2A 3626/4885 |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, JAK2 | PNMT 1460/4885MAPT 2492/4885ADRA2A 3439/4885 |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | PNMT 2367/4885MAPT 2051/4885ADRA2A 4344/4885 |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | CNR1, CNR2, ARRB1 | PNMT 2230/4885MAPT 2744/4885ADRA2A 23/4885 |
| US-11827609-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | PNMT 3496/4885MAPT 3599/4885ADRA2A 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.